Terms: = Pancreatic cancer AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990 AND Treatment
2 results:
1. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
Yamaue H; Tsunoda T; Tani M; Miyazawa M; Yamao K; Mizuno N; Okusaka T; Ueno H; Boku N; Fukutomi A; Ishii H; Ohkawa S; Furukawa M; Maguchi H; Ikeda M; Togashi Y; Nishio K; Ohashi Y
Cancer Sci; 2015 Jul; 106(7):883-90. PubMed ID: 25867139
[TBL] [Abstract] [Full Text] [Related]
2. Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.
Kohaar I; Porter-Gill P; Lenz P; Fu YP; Mumy A; Tang W; Apolo AB; Rothman N; Baris D; Schned AR; Ylaya K; Schwenn M; Johnson A; Jones M; Kida M; Silverman DT; Hewitt SM; Moore LE; Prokunina-Olsson L
J Natl Cancer Inst; 2013 Jan; 105(1):69-73. PubMed ID: 23266392
[TBL] [Abstract] [Full Text] [Related]
